LR 19052
Alternative Names: LR-19052Latest Information Update: 20 Jun 2024
At a glance
- Originator LG Chem
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 30 Apr 2024 Preregistration for Type 2 diabetes mellitus in South Korea (unspecified route) (LG Chem pipeline, April 2024)
- 11 Apr 2024 LR 19052 is available for licensing as of 11 Apr 2024. https://innovation.lgchem.com/ResearchDevelopment/Partnership.do
- 13 Oct 2020 Phase-III clinical trials in Type 2 diabetes mellitus in South Korea (unspecified route) (LG Chem pipeline, October 2020)